NewLink Genetics (NLNK) Shares Down 12.8%
NewLink Genetics Corp (NASDAQ:NLNK) shares traded down 12.8% during trading on Friday . The company traded as low as $7.56 and last traded at $6.60. 812,550 shares traded hands during mid-day trading, an increase of 0% from the average session volume of 810,681 shares. The stock had previously closed at $7.57.
A number of research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a report on Wednesday, January 3rd. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Jefferies Group cut their price target on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Stifel Nicolaus upped their price target on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Finally, Cantor Fitzgerald set a $26.00 price target on shares of NewLink Genetics and gave the stock a “buy” rating in a report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $23.29.
The company has a market cap of $221.91, a price-to-earnings ratio of -2.79 and a beta of 1.15.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.